Clinical trials: Age-Related Maculopathy
Age-Related Macular Degeneration
A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy
The objectives of this study are to evaluate the safety and efficacy of intravitreal administration of Fovista® administered in combination with Lucentis® compared to Lucentis® monotherapy in subjects with subfoveal choroidal…
- Trial name
- NCT01944839
- Testing
- E10030, ranibizumab
- Where
- 115 sites in United States, Austria and 11 more
- Volunteers
- 619 people
- Sponsor
- Ophthotech Corporation
AMD, Age-Related Macular Degeneration
Post-market Clinical Investigation of the SING IMT System, Model NG SI IMT 3X in Patients With End-stage Age-related Macular Degeneration
The objective of this study is to demonstrate the safety and effectiveness of the SING IMT (Smaller Incision New Generation Implantable Miniature Telescope) 3X implant in improving vision in patients with central vision…
- Trial name
- NCT04796545
- Testing
- SING IMT(TM) System, model NG SI IMT 3X
- Where
- 13 sites in Belgium, France and 5 more
- Volunteers
- 68 people
- Sponsor
- VisionCare, Inc.
Age Related Macular Degeneration, Choroidal Neovascularization
Genetic Analysis of Chronic Central Serous Chorioretinopathy Masquerading as Neovascular AMD
The study will be designed as a case control evaluation to compare the genetic profiles of three groups of patients categorized according to diagnosis.
- Conditions
- Age Related Macular Degeneration, Choroidal Neovascularization, Central Serous Chorioretinopathy
- Trial name
- NCT01880788
- Where
- United States
- Volunteers
- 152 people
- Sponsor
- Sequenom, Inc.
Nonexudative Age Related Macular Degeneration
Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration
This is a Phase II/III vehicle controlled, double masked, single center study. A single eye of 60 individuals with mild to moderate nonexudative Age-Related Macular Degeneration (AMD) will be randomly assigned to receive either…
- Trial name
- NCT01601483
- Testing
- MC-1101, MC-1101 Vehicle
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- MacuCLEAR, Inc.
Glaucoma, Diabetic Retinopathy (DR)
"My Eyes, My Light": Amar Chokh, Amar Alo
Eye disease affects 2.2 billion people globally, which in turn adversely affects schooling, economic productivity, and participation in social life.
- Conditions
- Glaucoma, Diabetic Retinopathy (DR), Hypertensive Retinopathy, Cataract
- Trial name
- ACA2 (NCT07135570)
- Testing
- Multimodal Screening for Eye Disease, cataract surgery
- Where
- Bangladesh
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Data Yakka, Inc.
Age Related Macular Degeneration, Choroidal Neovascularization
Comparison Between Home Macular Perimeter and Optical Coherence Tomography (OCT) Visual Field Defects in Patients With Choroidal Neovascularization (CNV)
The FORESEE HOME is intended for the early detection of central and paracentral irregularities (abnormalities) in the visual field, most commonly associated with Age Related Macular Degeneration (AMD).
- Trial name
- NCT01336907
- Where
- France
- Sponsor
- Notal Vision Ltd.
Age-Related Macular Degeneration
Study of Safety and Efficacy of Brolucizumab 6 mg Dosed Every 4 Weeks Compared to Aflibercept 2 mg Dosed Every 4 Weeks in Patients With Retinal Fluid Despite Frequent Anti-VEGF Injections
This clinical study was designed to compare the safety and efficacy of brolucizumab 6 mg dosed every 4 weeks to aflibercept 2 mg dosed every 4 weeks in those neovascular age-related macular degeneration (nAMD) patients with…
- Trial name
- MERLIN (NCT03710564)
- Testing
- Brolucizumab, Aflibercept
- Where
- 61 sites in United States, Puerto Rico
- Volunteers
- 535 people
- Sponsor
- Novartis Pharmaceuticals
Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration
A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
The study will compare the safety of ophthalmic bevacizumab in vials versus pre-filled syringes in subjects diagnosed with a retinal condition that would benefit from treatment with intravitreal injection of bevacizumab…
- Conditions
- Age-Related Macular Degeneration, Neovascular Age-related Macular Degeneration, Wet Macular Degeneration, BRVO - Branch Retinal Vein Occlusion
- Trial name
- NORSE SEVEN (NCT05112861)
- Testing
- bevacizumab
- Where
- 3 sites in United States
- Volunteers
- 120 people
- Sponsor
- Outlook Therapeutics, Inc.
Glaucoma, Age-Related Macular Degeneration
Detecting Eye Diseases Via Hybrid Deep Learning Algorithms From Fundus Images
Eye health is of great importance for quality of life. Some eye diseases can progress and cause permanent damage up to vision loss if they are not treated early.
- Conditions
- Glaucoma, Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
- Trial name
- NCT06213896
- Testing
- Mydriatic Agent, Color Fundus Photography, EyeCheckup v2.0
- Where
- Turkey (Türkiye)
- Volunteers
- 1,528 people, healthy volunteers welcome
- Sponsor
- Ural Telekomunikasyon Sanayi Ticaret Anonim Sirketi
Neovascular Age-related Macular Degeneration
A Study to Evaluate the Efficacy and Safety of IBI302 in Subjects With nAMD
The study is designed for multi-center,randomized,double-masked,active-contralled study to evaluate effective and security of intravitreal injection of IBI302 in subjects with neovascular age-related macular degeneration.
- Trial name
- NCT05972473
- Testing
- Aflibercept Ophthalmic, IBI302
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Geographic Atrophy, Age-related Macular Degeneration
A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
The main purpose of this study is to assess the ocular and systemic safety and tolerability of RO7669330 in participants with GA secondary to AMD in at least one eye in Part 1, or both eyes in Part 2, after multiple unilateral…
- Trial name
- NCT06961370
- Testing
- RO7669330, Syfovre™, Izervay™
- Where
- 17 sites in United States
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Neovascular Age-related Macular Degeneration
Evaluation the Pharmacokinetics,Safety,Tolerability of Single Intravitreal Injection RC28-E in Subjects With Wet Age-Related Macular Degeneration
The purpose of this first-in-human study is to evaluate the safety, tolerability and pharmacokinetics of single intravitreous injections,single ascending doses, of RC28-E(a chimeric decoy receptor trap fusion protein by dual…
- Trial name
- NCT03777254
- Testing
- RC28-E
- Where
- China
- Volunteers
- 12 people
- Sponsor
- RemeGen Co., Ltd.
Macular Degeneration
Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with neovascular age-related macular degeneration (nAMD)
- Trial name
- NCT02540954
- Testing
- Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
- Where
- 71 sites in Austria, Canada and 12 more
- Volunteers
- 336 people
- Sponsor
- Bayer
Dry Age-related Macular Degeneration
Feasibility Study of Compensation for Blindness With the PRIMA System in Patients With Dry Age Related Macular Degeneration
In this study, the principle functionality of the device will be tested in humans for the first time. The study will evaluate the extent to which patients with atrophic dry age related macular degeneration (AMD) have evoked light…
- Trial name
- PRIMA FS (NCT03333954)
- Testing
- PRIMA Bionic Vision System
- Where
- France
- Volunteers
- 5 people
- Sponsor
- Science Corporation
Neovascular (Wet) Age-related Macular Degeneration (nAMD)
A Study of EXG102-031 in Patients With wAMD (Everest)
In neovascular (wet) age-related macular degeneration (nAMD), the macula, or the part of the eye that provides the clear, detailed central vision, is being affected by abnormal blood vessel growth and leakage.
- Trial name
- NCT05903794
- Testing
- EXG102-031
- Where
- 2 sites in United States
- Volunteers
- 12 people
- Sponsor
- Exegenesis Bio
Age-Related Maculopathy, Age-Related Maculopathies
Safety And Tolerability Study Of RN6G In Subjects With Advanced Dry, Age-Related Macular Degeneration Including Geographic Atrophy
The purpose of this study is to determine the safety and tolerability of multiple doses of RN6G in subjects with advanced dry, age-related macular degeneration including geographic atrophy.
- Conditions
- Age-Related Maculopathy, Age-Related Maculopathies, Eye Diseases, Retinal Degeneration
- Trial name
- NCT01003691
- Testing
- RN6G
- Where
- 24 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pfizer
Neovascular Age-Related Macular Degeneration
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (Ocular Therapeutix) (Axitinib Implant) in Subjects With Neovascular Age-Related Macular Degeneration
Study to Evaluate the Efficacy and Safety of Intravitreal OTX-TKI (axitinib implant) in Subjects with Neovascular Age-Related Macular Degeneration
- Trial name
- NCT06223958
- Testing
- OTX-TKI (axitinib implant), Aflibercept
- Where
- 108 sites in United States, Argentina and 1 more
- Volunteers
- 344 people
- Sponsor
- Ocular Therapeutix, Inc.
Age-related Macular Degeneration (AMD)
Real-world Evaluation of Prevalence of Ocular Adverse Events in Patients With Neovascular (Wet) Agerelated Macular Degeneration (AMD) Who Received Anti-VEGF Agents (IRIS Registry)
In this cross-sectional study of patients with wet AMD who received ≥1 anti-VEGF injection (excluding brolucizumab), evidence was generated to describe the period prevalence of specific ocular AEs.
- Trial name
- NCT05110209
- Testing
- Aflibercept, Ranibizumab, Bevacizumab
- Where
- United States
- Volunteers
- 331,541 people
- Sponsor
- Novartis Pharmaceuticals
Macular Degeneration
Open Label Study for the Evaluation of Tolerability of Five Dose Levels of Cand5
To establish the tolerability and preliminary efficacy of Cand5 by a single intravitreal injection in patients with wet age-related macular degeneration.
- Trial name
- NCT00722384
- Testing
- bevasiranib
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- OPKO Health, Inc.
Neovascular Age-related Macular Degeneration
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration [LUNA]
Neovascular or wet age-related macular degeneration (nAMD) is a degenerative ocular disease associated with the infiltration of abnormal blood vessels in the retina from the underlying choroid layer and is a leading cause of…
- Trial name
- NCT05536973
- Testing
- ADVM-022
- Where
- 39 sites in United States, France and 1 more
- Volunteers
- 69 people
- Sponsor
- Adverum Biotechnologies, Inc.